Joseph Douglas Lyon net worth and biography

Joseph Lyon Biography and Net Worth

Currently, J. D. Lyon is Chief Accounting Officer of Corcept Therapeutics, Inc.

In the past he occupied the position of Director-Operations Business Development at Connor Group, Worldwide Corporate Controller & General Manager at Zinfi Technologies, Inc. and Auditor at Ernst & Young, Inc.

He received an undergraduate degree from the University of Utah.

What is Joseph Douglas Lyon's net worth?: The estimated net worth of Joseph Douglas Lyon is at least $521,076.10 as of July 1st, 2024. Mr. Lyon owns 9,290 shares of Corcept Therapeutics stock worth more than $521,076 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Lyon may own. Learn More about Joseph Douglas Lyon's net worth.
How old is Joseph Douglas Lyon?: Mr. Lyon is currently 46 years old. There are 7 older executives and no younger executives at Corcept Therapeutics. The oldest executive at Corcept Therapeutics is Dr. Joseph K. Belanoff M.D., Co-Founder, President, CEO & Director, who is 67 years old. Learn More on Joseph Douglas Lyon's age.
How do I contact Joseph Douglas Lyon?: The corporate mailing address for Mr. Lyon and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected]. Learn More on Joseph Douglas Lyon's contact information.
Has Joseph Douglas Lyon been buying or selling shares of Corcept Therapeutics?: Joseph Douglas Lyon has not been actively trading shares of Corcept Therapeutics within the last three months. Most recently, Joseph Douglas Lyon sold 5,000 shares of the business's stock in a transaction on Monday, July 1st. The shares were sold at an average price of $32.49, for a transaction totalling $162,450.00. Following the completion of the sale, the insider now directly owns 9,290 shares of the company's stock, valued at $301,832.10. Learn More on Joseph Douglas Lyon's trading history.
Who are Corcept Therapeutics' active insiders?: Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Belanoff (CEO), William Guyer (Chief Development Officer), Hazel Hunt (Insider), Joseph Lyon (CAO), Sean Maduck (Insider), David Mahoney (Director), Gary Robb (CFO), and Daniel Swisher, Jr. (Director). Learn More on Corcept Therapeutics' active insiders.
Are insiders buying or selling shares of Corcept Therapeutics?: In the last year, insiders at the biotechnology company sold shares 32 times. They sold a total of 269,472 shares worth more than $7,991,445.07. The most recent insider tranaction occured on November, 11th when Director Daniel N. Swisher, Jr. sold 2,200 shares worth more than $131,736.00. Insiders at Corcept Therapeutics own 20.5% of the company. Learn More about insider trades at Corcept Therapeutics.
Information on this page was last updated on 11/11/2024.

Joseph Douglas Lyon Insider Trading History at Corcept Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/1/2024	Sell	5,000	$32.49	$162,450.00	9,290
6/3/2024	Sell	5,000	$30.18	$150,900.00	7,314
5/9/2024	Sell	7,227	$26.00	$187,902.00	7,314
5/2/2024	Sell	10,830	$26.00	$281,580.00	7,314
4/4/2024	Sell	5,443	$26.00	$141,518.00	7,314
4/1/2024	Sell	500	$26.01	$13,005.00	7,314
2/16/2024	Sell	1,000	$26.00	$26,000.00	6,774
12/4/2023	Sell	2,432	$26.00	$63,232.00	5,854
12/1/2023	Sell	2,568	$26.00	$66,768.00	5,854
11/2/2023	Sell	3,977	$28.11	$111,793.47	5,854
10/6/2023	Sell	2,582	$27.24	$70,333.68	5,854
10/2/2023	Sell	2,418	$27.25	$65,890.50	5,854
9/1/2023	Sell	5,000	$32.73	$163,650.00	5,132
8/21/2023	Sell	4,588	$31.19	$143,099.72	5,132
8/7/2023	Sell	412	$31.22	$12,862.64	4,720
6/6/2023	Sell	10,000	$23.60	$236,000.00	5,132
4/1/2021	Sell	25,000	$23.88	$597,000.00	25,000
2/3/2021	Sell	25,000	$29.18	$729,500.00	25,000
1/4/2021	Sell	25,000	$26.13	$653,250.00	4,167

Joseph Douglas Lyon Buying and Selling Activity at Corcept Therapeutics

Corcept Therapeutics Company Overview

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Today's Range

Now: $56.09

$54.02

$56.13

50 Day Range

MA: $47.62

$35.71

$59.60

2 Week Range

Now: $56.09

$20.84

$61.66

Volume

1,013,492 shs

Average Volume

1,182,597 shs

Market Capitalization

$5.88 billion

P/E Ratio

44.52

Dividend Yield

N/A

Beta

0.45

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>

Joseph Lyon Biography and Net Worth

What is Joseph Douglas Lyon's net worth?

How old is Joseph Douglas Lyon?

How do I contact Joseph Douglas Lyon?

Has Joseph Douglas Lyon been buying or selling shares of Corcept Therapeutics?

Who are Corcept Therapeutics' active insiders?

Are insiders buying or selling shares of Corcept Therapeutics?